Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Non-Current Debt: 2020-2024

Historic Non-Current Debt for Syndax Pharmaceuticals (SNDX) over the last 3 years, with Dec 2024 value amounting to $331.6 million.

  • Syndax Pharmaceuticals' Non-Current Debt was N/A to $331.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was $331.6 million, marking a year-over-year change of. This contributed to the annual value of $331.6 million for FY2024, which is N/A change from last year.
  • Per Syndax Pharmaceuticals' latest filing, its Non-Current Debt stood at $331.6 million for FY2024, which was up 1,566.57% from $19.9 million recorded in FY2021.
  • Syndax Pharmaceuticals' 5-year Non-Current Debt high stood at $331.6 million for FY2024, and its period low was $17.8 million during FY2020.
  • For the 1-year period, Syndax Pharmaceuticals' Non-Current Debt averaged around $331.6 million, with its median value being $331.6 million (2024).
  • Data for Syndax Pharmaceuticals' Non-Current Debt shows a peak YoY rose of 11.56% (in 2021) over the last 5 years.
  • Syndax Pharmaceuticals' Non-Current Debt (Yearly) stood at $17.8 million in 2020, then climbed by 11.56% to $19.9 million in 2021, then reached $331.6 million in 2024.